Local and Systemic Interleukin-32 in Esophageal, Gastric, and Colorectal Cancers: Clinical and Diagnostic Significance
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Population
2.2. Ethical Considerations
2.3. Analytical Methods
2.3.1. IL32 Expression in Tissue Samples
2.3.2. IL-32 Concentration in Tissue Homogenates
2.3.3. IL-32 Concentration in Serum Samples
2.4. Statistical Analysis
3. Results
3.1. Local IL-32 Expression at mRNA Level
3.2. Local IL-32 Protein Concentration
3.3. Systemic IL-32 Protein Concentration
4. Discussion
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
Abbreviations
AUC | Area under the ROC curve |
CI | Confidence interval |
COX | Cyclooxygenase |
CRC | Colorectal adenocarcinoma |
EMT | Epithelial-mesenchymal transition |
ESCC | Esophageal squamous cell carcinoma |
FGF | Fibroblast growth factor |
GC | Gastric adenocarcinoma |
G-CSF | Granulocyte colony-stimulating factor |
GIT | Gastrointestinal tract |
GM-CSF | Granulocyte-macrophage colony-stimulating factor |
IBD | Inflammatory bowel disease |
IFN | Interferon |
IL | Interleukin |
MCP | Monocyte chemoattractant protein |
MIP | Macrophage inflammatory protein |
NOS | Nitric oxide synthase |
NRQ | Normalized relative quantities |
PDGF | Platelet-derived growth factor |
ROC | Receiver operating characteristics |
RT-qPCR | Reverse-transcribed quantitative (real-time) polymerase chain reaction |
TNF | Tumor necrosis factor |
TNM | Tumor-node-metastasis cancer staging system |
VEGF | Vascular endothelial growth factor |
References
- Bray, F.; Ferlay, J.; Soerjomataram, I.; Siegel, R.L.; Torre, L.A.; Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018, 68, 394–424. [Google Scholar] [CrossRef] [Green Version]
- Tustumi, F.; Kimura, C.M.; Takeda, F.R.; Uema, R.H.; Salum, R.A.; Ribeiro-Junior, U.; Cecconello, I. Prognostic Factors and Survival Analysis in Esophageal Carcinoma. ABCD Arq. Bras. Cir. Dig. 2016, 29, 138–141. [Google Scholar] [CrossRef] [PubMed]
- Thrift, A.P.; El-Serag, H.B. Burden of Gastric Cancer. Clin. Gastroenterol. Hepatol. 2020, 18, 534–542. [Google Scholar] [CrossRef] [PubMed]
- Kumar, K.V.V.; Sagar, R.; Mathew, J. Squamous cell carcinoma: Esophagus. In Squamous Cell Carcinoma—Hallmark and Treatment Modalities; Daaboul, H.E., Ed.; IntechOpen Ltd.: London, UK, 2019. [Google Scholar] [CrossRef] [Green Version]
- Takahashi, T.; Saikawa, Y.; Kitagawa, Y. Gastric cancer: Current status of diagnosis and treatment. Cancers 2013, 5, 48–63. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aftimos, P.G.; Barthelemy, P.; Awada, A. Molecular Biology in Medical Oncology: Diagnosis, Prognosis, and Precision Medicine. Discov. Med. 2014, 17, 81–91. [Google Scholar]
- Yang, J.W.; Choi, Y.L. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine. Pathol. Res. Pract. 2017, 213, 836–841. [Google Scholar] [CrossRef]
- Liu, X.; Meltzer, S.J. Gastric Cancer in the Era of Precision Medicine. Cell Mol. Gastroenterol. Hepatol. 2017, 3, 348–358. [Google Scholar] [CrossRef] [Green Version]
- Aziz, M.A. Precision medicine in colorectal cancer. Saudi J. Gastroenterol. 2019, 25, 139–140. [Google Scholar] [CrossRef]
- Kim, E.R.; Chang, D.K. Colorectal cancer in inflammatory bowel disease: The risk, pathogenesis, prevention and diagnosis. World J. Gastroenterol. 2014, 20, 9872–9881. [Google Scholar] [CrossRef]
- O’Sullivan, K.E.; Phelan, J.J.; O’Hanlon, C.; Lysaght, J.; O’Sullivan, J.N.; Reynolds, J.V. The role of inflammation in cancer of the esophagus. Expert Rev. Gastroenterol. Hepatol. 2014, 8, 749–760. [Google Scholar] [CrossRef]
- Rajput, S.; Wilber, A. Roles of inflammation in cancer initiation, progression, and metastasis. Front. Biosci. 2010, 2, 176–183. [Google Scholar] [CrossRef] [Green Version]
- Joosten, L.A.; Heinhuis, B.; Netea, M.G.; Dinarello, C.A. Novel insights into the biology of interleukin-32. Cell Mol. Life Sci. 2013, 70, 3883–3892. [Google Scholar] [CrossRef] [PubMed]
- Khawar, M.B.; Abbasi, M.H.; Sheikh, N. IL-32: A Novel Pluripotent Inflammatory Interleukin, towards Gastric Inflammation, Gastric Cancer, and Chronic Rhino Sinusitis. Mediators Inflamm. 2016, 2016, 8413768. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Han, S.; Yang, Y. Interleukin-32: Frenemy in cancer? BMB Rep. 2019, 52, 165–174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yan, H.; He, D.; Huang, X.; Zhang, E.; Chen, Q.; Xu, R.; Liu, X.; Zi, F.; Cai, Z. Role of interleukin-32 in cancer biology. Oncol. Lett. 2018, 16, 41–47. [Google Scholar] [CrossRef]
- Shioya, M.; Nishida, A.; Yagi, Y.; Ogawa, A.; Tsujikawa, T.; Kim-Mitsuyama, S.; Takayanagi, A.; Shimizu, N.; Fujiyama, Y.; Andoh, A. Epithelial overexpression of interleukin-32alpha in inflammatory bowel disease. Clin. Exp. Immunol. 2007, 149, 480–486. [Google Scholar] [CrossRef]
- Sloot, Y.J.E.; Smit, J.W.; Joosten, L.A.B.; Netea-Maier, R.T. Insights into the role of IL-32 in cancer. Semin. Immunol. 2018, 38, 24–32. [Google Scholar] [CrossRef]
- Tsai, C.Y.; Wang, C.S.; Tsai, M.M.; Chi, H.C.; Cheng, W.L.; Tseng, Y.H.; Chen, C.Y.; Lin, C.D.; Wu, J.I.; Wang, L.H. Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis. Clin. Cancer Res. 2014, 20, 2276–2288. [Google Scholar] [CrossRef] [Green Version]
- Bak, Y.; Kwon, T.; Bak, I.S.; Hong, J.; Yu, D.Y.; Yoon, D.Y. IL-32θ inhibits stemness and epithelial-mesenchymal transition of cancer stem cells via the STAT3 pathway in colon cancer. Oncotarget 2016, 7, 7307–7317. [Google Scholar] [CrossRef] [Green Version]
- Hellemans, J.; Vandesompele, J. qPCR data analysis—Unlocking the secret to successful results. In PCR Troubleshooting and Optimization: The Essential Guide, 1st ed.; Kennedy, S., Oswald, N., Eds.; Caister Academic Press: Poole, UK, 2011; pp. 1–13. [Google Scholar]
- Bednarz-Misa, I.; Diakowska, D.; Szczuka, I.; Fortuna, P.; Kubiak, A.; Rosińczuk, J.; Krzystek-Korpacka, M. Interleukins 4 and 13 and Their Receptors Are Differently Expressed in Gastrointestinal Tract Cancers, Depending on the Anatomical Site and Disease Advancement, and Improve Colon Cancer Cell Viability and Motility. Cancers 2020, 12, 1463. [Google Scholar] [CrossRef]
- Bednarz-Misa, I.; Fortuna, P.; Diakowska, D.; Jamrozik, N.; Krzystek-Korpacka, M. Distinct Local and Systemic Molecular Signatures in the Esophageal and Gastric Cancers: Possible Therapy Targets and Biomarkers for Gastric Cancer. Int. J. Mol. Sci. 2020, 21, 4509. [Google Scholar] [CrossRef] [PubMed]
- Krzystek-Korpacka, M.; Diakowska, D.; Kapturkiewicz, B.; Bębenek, M.; Gamian, A. Profiles of circulating inflammatory cytokines in colorectal cancer (CRC), high cancer risk conditions, and health are distinct. Possible implications for CRC screening and surveillance. Cancer Lett. 2013, 337, 107–114. [Google Scholar] [CrossRef] [PubMed]
- Seo, E.H.; Kang, J.; Kim, K.H.; Cho, M.C.; Lee, S.; Kim, H.J.; Kim, J.H.; Kim, E.J.; Park, D.K.; Kim, S.H. Detection of expressed IL-32 in human stomach cancer using ELISA and immunostaining. J. Microbiol. Biotechnol. 2008, 18, 1606–1612. [Google Scholar] [PubMed]
- Erturk, K.; Tastekin, D.; Serilmez, M.; Bilgin, E.; Bozbey, H.U.; Vatansever, S. Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer. Tumour Biol. 2016, 37, 405–412. [Google Scholar] [CrossRef] [PubMed]
- Catalán, V.; Gómez-Ambrosi, J.; Rodríguez, A.; Ramírez, B.; Ortega, V.A.; Hernández-Lizoain, J.L.; Baixauli, J.; Becerril, S.; Rotellar, F.; Valentí, V. IL-32α-induced inflammation constitutes a link between obesity and colon cancer. Oncoimmunology 2017, 6, e1328338. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yousif, N.G.; Al-Amran, F.G.; Hadi, N.; Lee, J.; Adrienne, J. Expression of IL32 modulates NF-κB and p38 MAP kinase pathways in human esophageal cancer. Cytokine 2013, 61, 223–227. [Google Scholar] [CrossRef] [PubMed]
- Schlesinger-Raab, A.; Werner, J.; Friess, H.; Hölzel, D.; Engel, J. Age and outcome in gastrointestinal cancers: A population-based evaluation of oesophageal, gastric and colorectal cancer. Visc. Med. 2017, 33, 245–253. [Google Scholar] [CrossRef]
- Li, Y.; Xie, J.; Xu, X.; Liu, L.; Wan, Y.; Liu, Y.; Zhu, C.; Zhu, Y. Inducible interleukin 32 (IL-32) exerts extensive antiviral function via selective stimulation of interferon λ1 (IFN-λ1). J. Biol. Chem. 2013, 288, 20927–20941. [Google Scholar] [CrossRef] [Green Version]
- He, J.; Ye, W.; Kou, N.; Chen, K.; Cui, B.; Zhang, X.; Hu, S.; Liu, T.; Kang, L.; Li, X. MicroRNA-29b-3p suppresses oral squamous cell carcinoma cell migration and invasion via IL32/AKT signalling pathway. J. Cell. Mol. Med. 2020, 24, 841–849. [Google Scholar] [CrossRef] [Green Version]
- Oliveto, S.; Mancino, M.; Manfrini, N.; Biffo, S. Role of microRNAs in translation regulation and cancer. World J. Biol. Chem. 2017, 8, 45–56. [Google Scholar] [CrossRef]
- Sorrentino, C.; Di Carlo, E. Expression of IL32 in human lung cancer is related to the histotype and metastatic phenotype. Am. J. Respir. Crit. Care Med. 2009, 180, 769–779. [Google Scholar] [CrossRef] [PubMed]
- Nabeki, B.; Ishigami, S.; Uchikado, Y.; Sasaki, K.; Kita, Y.; Okumura, H.; Arigami, T.; Kijima, Y.; Kurahara, H.; Maemura, K. Interleukin-32 expression and Treg infiltration in esophageal squamous cell carcinoma. Anticancer Res. 2015, 35, 2941–2947. [Google Scholar] [PubMed]
- Ishigami, S.; Arigami, T.; Uchikado, Y.; Setoyama, T.; Kita, Y.; Sasaki, K.; Okumura, H.; Kurahara, H.; Kijima, Y.; Harada, A. IL32 expression is an independent prognostic marker for gastric cancer. Med. Oncol. 2013, 30, 472. [Google Scholar] [CrossRef]
- Neubauer, K.; Bednarz-Misa, I.; Diakowska, D.; Kapturkiewicz, B.; Gamian, A.; Krzystek-Korpacka, M. Nampt/PBEF/visfatin upregulation in colorectal tumors, mirrored in normal tissue and whole blood of colorectal cancer patients, is associated with metastasis, hypoxia, IL1β, and anemia. Biomed. Res. Int. 2015, 2015, 523930. [Google Scholar] [CrossRef] [Green Version]
- Krzystek-Korpacka, M.; Gorska, S.; Diakowska, D.; Kapturkiewicz, B.; Podkowik, M.; Gamian, A.; Bednarz-Misa, I. Midkine is up-regulated in both cancerous and inflamed bowel, reflecting lymph node metastasis in colorectal cancer and clinical activity of ulcerative colitis. Cytokine 2017, 89, 68–75. [Google Scholar] [CrossRef]
- Bednarz-Misa, I.; Diakowska, D.; Krzystek-Korpacka, M. Local and systemic IL-7 concentration in gastrointestinal-tract cancers. Medicina 2019, 55, 262. [Google Scholar] [CrossRef] [Green Version]
- Mao, L.; Clark, D. Molecular margin of surgical resections—where do we go from here? Cancer 2015, 121, 1914–1916. [Google Scholar] [CrossRef] [PubMed]
- Dakubo, G.D.; Jakupciak, J.P.; Birch-Machin, M.A.; Parr, R.L. Clinical implications and utility of field cancerization. Cancer Cell Int. 2007, 7, 2. [Google Scholar] [CrossRef] [Green Version]
- Patel, A.; Tripathi, G.; Gopalakrishnan, K.; Williams, N.; Arasaradnam, R.P. Field cancerisation in colorectal cancer: A new frontier or pastures past? World J. Gastroenterol. 2015, 21, 3763–3772. [Google Scholar] [CrossRef]
- Sakitani, K.; Hirata, Y.; Hayakawa, Y.; Serizawa, T.; Nakata, W.; Takahashi, R.; Kinoshita, H.; Sakamoto, K.; Nakagawa, H.; Akanuma, M. Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation. Infect. Immun. 2012, 80, 3795–3803. [Google Scholar] [CrossRef] [Green Version]
- Chang, W.J.; Du, Y.; Zhao, X.; Ma, L.Y.; Cao, G.W. Inflammation-related factors predicting prognosis of gastric cancer. World J. Gastroenterol. 2014, 20, 4586–4596. [Google Scholar] [CrossRef] [PubMed]
- Yun, H.M.; Park, K.R.; Kim, E.C.; Han, S.B.; Yoon, D.Y.; Hong, J.T. IL-32α suppresses colorectal cancer development via TNFR1-mediated death signaling. Oncotarget 2015, 6, 9061–9072. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Park, E.S.; Yoo, J.M.; Yoo, H.S.; Yoon, D.Y.; Yun, Y.P.; Hong, J. IL-32γ enhances TNF-α-induced cell death in colon cancer. Mol. Carcinog. 2014, 53 (Suppl. 1), E23–E35. [Google Scholar] [CrossRef] [PubMed]
- Yun, H.M.; Oh, J.H.; Shim, J.H.; Ban, J.O.; Park, K.R.; Kim, J.H.; Lee, D.H.; Kang, J.W.; Park, Y.H.; Yu, D. Antitumor activity of IL-32β through the activation of lymphocytes, and the inactivation of NF-κB and STAT3 signals. Cell Death Dis. 2013, 4, e640. [Google Scholar] [CrossRef]
- Oh, J.H.; Cho, M.C.; Kim, J.H.; Lee, S.Y.; Kim, H.J.; Park, E.S.; Ban, J.O.; Kang, J.W.; Lee, D.H.; Shim, J.H. IL-32γ inhibits cancer cell growth through inactivation of NF-κB and STAT3 signals. Oncogene 2011, 30, 3345–3359. [Google Scholar] [CrossRef] [Green Version]
- Yang, Y.; Wang, Z.; Zhou, Y.; Wang, X.; Xiang, J.; Chen, Z. Dysregulation of over-expressed IL-32 in colorectal cancer induces metastasis. World J. Surg. Oncol. 2015, 13, 146. [Google Scholar] [CrossRef] [Green Version]
- Hemminki, K.; Santi, I.; Weires, M.; Thomsen, H.; Sundquist, J.; Bermejo, J.L. Tumor location and patient characteristics of colon and rectal adenocarcinomas in relation to survival and TNM classes. BMC Cancer 2010, 10, 688. [Google Scholar] [CrossRef] [Green Version]
- Greystoke, A.; Mullamitha, S.A. How many diseases are colorectal cancer? Gastroenterol. Res. Pract. 2012, 2012, 564741. [Google Scholar] [CrossRef]
- Yamauchi, M.; Lochhead, P.; Morikawa, T.; Huttenhower, C.; Chan, A.T.; Giovannucci, E.; Fuchs, C.; Ogino, S. Colorectal cancer: A tale of two sides or a continuum? Gut 2012, 61, 794–797. [Google Scholar] [CrossRef] [Green Version]
- Simons, C.C.; Hughes, L.A.; Smits, K.M.; Khalid-de Bakker, C.A.; de Bruïne, A.P.; Carvalho, B.; Meijer, G.A.; Schouten, L.J.; van den Brandt, P.A.; Weijenberg, M.P. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: Implications for prognosis. Ann. Oncol. 2013, 24, 2048–2056. [Google Scholar] [CrossRef]
- Krzystek-Korpacka, M.; Diakowska, D.; Grabowski, K.; Gamian, A. Tumor location determines midkine level and its association with the disease progression in colorectal cancer patients: A pilot study. Int. J. Colorectal. Dis. 2012, 27, 1319–1324. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krzystek-Korpacka, M.; Diakowska, D.; Neubauer, K.; Gamian, A. Circulating midkine in malignant and non-malignant colorectal diseases. Cytokine 2013, 64, 158–164. [Google Scholar] [CrossRef] [PubMed]
- Krzystek-Korpacka, M.; Zawadzki, M.; Neubauer, K.; Bednarz-Misa, I.; Górska, S.; Wiśniewski, J.; Witkiewicz, W.; Gamian, A. Elevated systemic interleukin-7 in patients with colorectal cancer and individuals at high risk of cancer: Association with lymph node involvement and tumor location in the right colon. Cancer Immunol. Immunother. 2017, 66, 171–179. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krzystek-Korpacka, M.; Zawadzki, M.; Kapturkiewicz, B.; Lewandowska, P.; Bednarz-Misa, I.; Gorska, S.; Witkiewicz, W.; Gamian, A. Subsite heterogeneity in the profiles of circulating cytokines in colorectal cancer. Cytokine 2018, 110, 435–441. [Google Scholar] [CrossRef] [PubMed]
- Zhao, W.B.; Wang, Q.L.; Xu, Y.T.; Xu, S.F.; Qiu, Y.; Zhu, F. Overexpression of interleukin-32α promotes invasion by modulating VEGF in hepatocellular carcinoma. Oncol. Rep. 2018, 39, 1155–1162. [Google Scholar] [CrossRef] [Green Version]
- Nold-Petry, C.A.; Rudloff, I.; Baumer, Y.; Ruvo, M.; Marasco, D.; Botti, P.; Farkas, L.; Cho, S.X.; Zepp, J.A.; Azam, T. IL-32 promotes angiogenesis. J. Immunol. 2014, 192, 589–602. [Google Scholar] [CrossRef] [Green Version]
- Meyer, N.; Christoph, J.; Makrinioti, H.; Indermitte, P.; Rhyner, C.; Soyka, M.; Eiwegger, T.; Chalubinski, M.; Wanke, K.; Fujita, H. Inhibition of angiogenesis by IL-32: Possible role in asthma. J. Allergy Clin. Immunol. 2012, 129, 964–973. [Google Scholar] [CrossRef]
- Dolivo, D.M.; Larson, S.A.; Dominko, T. Fibroblast Growth Factor 2 as an Antifibrotic: Antagonism of Myofibroblast Differentiation and Suppression of Pro-Fibrotic Gene Expression. Cytokine Growth Factor Rev. 2017, 38, 49–58. [Google Scholar] [CrossRef]
- Wang, S.; Chen, F.; Tang, L. IL-32 promotes breast cancer cell growth and invasiveness. Oncol. Lett. 2015, 9, 305–307. [Google Scholar] [CrossRef] [Green Version]
- Neuzillet, J.M.; Traynor, C.; Hullmann, G.; Tyritzis, G.; Shimizu, J. TNF-α-induced IL-32 expression in esophageal cancer: Cross talk JNK/Akt signaling pathways. Am. J. BioMed. 2013, 1, 73–85. [Google Scholar] [CrossRef]
- Ribeiro-Dias, F.; Saar Gomes, R.; de Lima Silva, L.L.; Dos Santos, J.C.; Joosten, L.A. Interleukin 32: A novel player in the control of infectious diseases. J. Leukoc Biol. 2017, 101, 39–52. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bednarz-Misa, I.; Bromke, M.; Krzystek-Korpacka, M. Interleukin (IL)-7 signaling in the tumor microenvironment. In Tumor Microenvironment; Birbrair, A., Ed.; Springer: Berlin/Heidelberg, Germany, in press.
Characteristics | Controls | ESCC | GC | CRC | p Value |
---|---|---|---|---|---|
n | 28 | 17 | 14 | 41 | - |
Sex (F/M), n | 12/16 | 7/10 | 4/10 | 21/20 | 0.515 1 |
Age [yrs.], median (95%CI) | 57 (53–61.6) | 61 (58–65) | 64 (58–75.3) | 59 (54–65.2) | 0.121 2 |
TNM stage (I/II/III/IV), n | - | 1/6/9/1 | 2/3/5/4 | 14/12/12/4 | 0.079 1 |
Primary tumor, T (1/2/3/4), n | - | 0/6/9/2 | 1/1/8/4 | 5/11/22/3 | 0.201 1 |
Lymph node metastasis, N (no/yes), n | - | 8/9 | 5/9 | 26/15 | 0.159 1 |
Distant metastasis, M (no/yes), n | - | 16/1 | 10/4 | 37/4 | 0.118 1 |
Gene | Tumor IL32 | Adjacent IL32 | Fold-Change (T/A) in IL32 |
---|---|---|---|
ACTA2 | 0.33, p = 0.031 | ns | ns |
BCL2 | 0.39, p = 0.019 | 0.39, p = 0.008 | ns |
BCLxL | 0.34, p = 0.023 | 0.57, p < 0.001 | 0.37, p = 0.015 |
CCL2 | 0.45, p = 0.002 | 0.32, p = 0.037 | 0.30, p = 0.049 |
CDKN1A | 0.27, p = 0.079 | 0.41, p = 0.006 | 0.51, p < 0.001 |
HIF1A | 0.57, p < 0.001 | 0.40, p = 0.007 | 0.31, p = 0.040 |
IL10 | 0.29, p = 0.053 | ns | ns |
IL10Ra | ns | 0.41, p = 0.005 | ns |
IL13Ra | 0.37, p = 0.012 | 0.40, p = 0.007 | ns |
IL7 | 0.32, p = 0.037 | 0.40, p = 0.007 | 0.41, p = 0.005 |
IL7Ra | ns | 0.37, p = 0.012 | 0.38, p = 0.011 |
Ki67 | 0.62, p < 0.001 | 0.49, p < 0.001 | 0.48, p = 0.001 |
ODC1 | 0.45, p = 0.002 | 0.35, p = 0.019 | 0.29, p = 0.056 |
PTGS2 | 0.30, p = 0.045 | ns | ns |
SLC2A1 | 0.54, p < 0.001 | 0.53, p < 0.001 | 0.55, p < 0.001 |
TJP1 | 0.39, p = 0.008 | 0.31, p = 0.041 | ns |
VEGFA | ns | 0.52, p < 0.001 | 0.46, p = 0.002 |
Cytokine/Growth Factor | Spearman Correlation Coefficient (ρ), p |
---|---|
FGF2 | −0.52, p < 0.001 |
G-CSF | 0.53, p < 0.001 |
MIP-1α | −0.35, p = 0.021 |
PDGF-BB | 0.46, p = 0.002 |
TNFα | 0.63, p < 0.001 |
VEGF-A | −0.52, p < 0.001 |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Diakowska, D.; Krzystek-Korpacka, M. Local and Systemic Interleukin-32 in Esophageal, Gastric, and Colorectal Cancers: Clinical and Diagnostic Significance. Diagnostics 2020, 10, 785. https://doi.org/10.3390/diagnostics10100785
Diakowska D, Krzystek-Korpacka M. Local and Systemic Interleukin-32 in Esophageal, Gastric, and Colorectal Cancers: Clinical and Diagnostic Significance. Diagnostics. 2020; 10(10):785. https://doi.org/10.3390/diagnostics10100785
Chicago/Turabian StyleDiakowska, Dorota, and Małgorzata Krzystek-Korpacka. 2020. "Local and Systemic Interleukin-32 in Esophageal, Gastric, and Colorectal Cancers: Clinical and Diagnostic Significance" Diagnostics 10, no. 10: 785. https://doi.org/10.3390/diagnostics10100785